Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis.

et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. A first-inhuman , phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. et al. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. Johnson AJ, et al. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. et al. Update on the phase I study of the cyclin dependent kinase inhibitor dinaciclib (SCH 727965) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): confirmation of clinical activity and feasibility of long-term administration [abstract]. et al. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. 17. Robak T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. et al. Three-year follow-up of treatment-na¨ıve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Over the past 4 decades, outcomes have improved dramatically among pediatric patients with acute lymphoblastic leukemia (ALL), with observed cure rates now .80% in developed countries. 1 This progress can be attributed, in part, to large cooperative group studies, advances in combination chemotherapy, monitoring of minimal residual disease , and use of tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome–positive (Ph 1) ALL. Recent series have reported excellent outcomes among adolescents and younger adults with ALL who have been treated with pediatric-inspired regimens. 2-4 Despite these advances, 5-year overall survival (OS) remains dismal (;20%) among adults age $60 years treated at academic centers and on multi-institutional clinical trials by using …